Fig. 3: Longitudinal analyses of SARS-CoV-2-specific CD8+ T cell responses.
From: Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells
Longitudinal analyses are shown of SARS-CoV-2-infected individual D1. a, Timeline showing bleed dates (red arrowheads: light red, early time points; dark red, late time points), symptoms (dark gray bar) and positive PCR testing depicted at d.p.s. The infection time point is indicated with six days prior to symptom onset. b, The calculated ex vivo frequencies of B*44/N322–330- and B*44/ORF1ab3946–3954-specific CD8+ T cells (10 to 20 × 106 PBMCs) are indicated versus d.p.s. together with a historic sample. The dashed line indicates the detection threshold. c, Anti-SARS-CoV-2 S IgG (black dots; EUROIMMUN test, detection limit: 1.2 a.u. ml−1) and anti-SARS-CoV-2 N IgG (gray squares; Mikrogen test, detection limit: 24 a.u. ml−1) are depicted versus d.p.s. The dashed line indicates the detection limit of both tests. d, Diffusion map showing flow cytometry data of B*44/N322–330- and B*44/ORF1ab3946–3954-specific CD8+ T cells in relation to d.p.s. Protein expression levels are plotted on the diffusion map. e, The dynamic expression profile of SARS-CoV-2-specific CD8+ T cells, visualized as a heatmap. Data were collected by mass cytometry. Heatmap coloring represents percent of virus-specific CD8+ T cells expressing a given marker (blue, low expression; red, high expression). f, Longitudinal analysis of SARS-CoV-2-infected individual D2. The timeline shows bleed dates, symptoms and positive PCR testing depicted at d.p.s. (left). The frequency of A*02/ORF3a139–147-specific T cells (middle) and anti-SARS-CoV-2 S IgG and anti-SARS-CoV-2 N IgG (right) are depicted at d.p.s. together with a historic sample. g, Longitudinal analysis of SARS-CoV-2-infected individual D3. The timeline shows bleed dates, symptoms and positive PCR testing depicted at d.p.s. (left). The frequency of A*01/ORF3a207–215- and A*01/ORF1ab4163–4172-specific T cells (middle) and anti-SARS-CoV-2 S IgG and anti-SARS-CoV-2 N IgG (right) are depicted versus d.p.s. together with a historic sample.
